Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~A participant was required to meet all of the following inclusion criteria to be eligible for participation in the study:~* Chronic Hepatitis B infection~* 18 through 69 years of age, inclusive~* HBV DNA ≥ 1000 copies/mL~* Decompensated liver disease with all of the following:~  * CPT score of 7-12 (inclusive) OR history of CPT score ≥ 7 and any CPT at screen ≤ 12~ * Serum alanine aminotransferase (ALT) \< 10 x the upper limit of the normal range (ULN)~ * Hemoglobin ≥ 7.5 g/dL~ * Total white blood cell (WBC) count ≥ 1,500/mm\^3~ * Platelet count ≥ 30,000/mm\^3~* Alpha-fetoprotein ≤ 20 ng/mL and ultrasound or other imaging with no evidence of hepatocellular carcinoma (HCC), or alpha-fetoprotein of 21-50 ng/mL and computed tomography (CT)/magnetic resonance imaging (MRI) scan with no evidence of HCC, within 6 months of screening~* Calculated creatinine clearance ≥ 50 mL/min~* Negative human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis D virus (HDV) serologies~* Less than 24 months of total prior adefovir dipivoxil exposure~* Willing and able to provide written informed consent~Exclusion Criteria:~A participant who met any of the following exclusion criteria could not be enrolled in the study:~* Pregnant women, women who were breastfeeding or who believed they may have wished to become pregnant during the course of the study~* Males and females of reproductive potential who were unwilling to use an effective method of contraception during the study~* Prior use of TDF or ETV~* History of variceal bleeding, hepatorenal syndrome, Grade 3 or 4 hepatic encephalopathy, or spontaneous bacterial peritonitis within 60 days of screening~* Grade 2 hepatic encephalopathy at screening~* History of solid organ or bone marrow transplant~* Current use of hepatotoxic drugs, nephrotoxic drugs, or drugs that interfere with renal tubular secretion~* Current therapy with immunomodulators (eg, corticosteroids, interleukin-2, etc.) or investigational drugs~* Diagnosis of proximal tubulopathy~* Use of investigational agent within 30 days prior to screening~* Known hypersensitivity to TDF, FTC, ETV, or formulation excipients of any of the study drug products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Tenofovir DF (Type: EXPERIMENTAL): TDF 300 mg + FTC/TDF placebo + ETV placebo once daily (QD)
- FTC/TDF (Type: EXPERIMENTAL): FTC 200 mg/TDF 300 mg + TDF placebo + ETV placebo QD
- Entecavir (Type: EXPERIMENTAL): ETV 0.5 mg or 1 mg + TDF placebo + FTC/TDF placebo QD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete